MOTS-c — Research Overview
Full Name: Mitochondrial Open Reading Frame of the 12S rRNA Type-C Abbreviation: MOTS-c Sequence: 16 amino acid peptide encoded by a 51-base pair short open reading frame (sORF) within the mitochondrial 12S rRNA gene (MT-RNR1) Origin: Mitochondrial genome — making MOTS-c unique among all peptides in this research catalog as the only one encoded not in nuclear DNA but in the independent mitochondrial genome. This distinguishes MOTS-c from all nuclear-genome-encoded peptides, hormones, and research compounds. Discovery: 2015, University of Southern California (Changhan David Lee, Pinchas Cohen laboratory), published in Cell Metabolism Phylogenetic Conservation: The first 11 amino acid residues of MOTS-c are highly conserved across at least 14 mammalian species — reflecting strong positive evolutionary selection pressure on a sequence within one of the most mutation-prone genomes in biology, indicating critical functional importance. Category: Mitochondria-derived peptide (MDP) / mitochondrial retrograde signaling molecule / AMPK activator / exercise mimetic / metabolic regulator / stress response peptide / aging research tool
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is MOTS-c?
MOTS-c is a 16-amino acid peptide with a scientific origin story unlike any other compound in this catalog. It is encoded not in nuclear DNA — the conventional genome — but within a short open reading frame of the mitochondrial 12S ribosomal RNA gene. This origin from the mitochondrial genome is scientifically extraordinary and was not anticipated. For decades, the mitochondrial genome was understood to encode exactly 13 proteins (all components of the electron transport chain), 2 ribosomal RNAs, and 22 transfer RNAs — a fixed inventory assumed to be complete. The discovery of functional peptide-encoding short open reading frames (sORFs) within mitochondrial ribosomal RNA genes fundamentally revised this assumption, revealing an entirely new layer of mitochondrial coding potential that had been overlooked.
MOTS-c belongs to an emerging class of molecules called mitochondria-derived peptides (MDPs), which includes humanin (encoded by the 16S rRNA), the SHLP family (short humanin-like peptides 1-6, also from 16S rRNA), and SHMOOSE (encoded from a region overlapping a serine tRNA). MOTS-c is the only MDP encoded by the 12S rRNA region and has a functionally distinct profile from humanin and the SHLPs — most notably its exercise-induction, its AMPK-centered metabolic mechanism, and its unique capacity for retrograde mitochondria-to-nucleus translocation and direct nuclear gene regulation.
The biological significance of MOTS-c lies in what it represents conceptually as much as in its specific effects. For the first time, research has established that the mitochondrial genome — an evolutionarily ancient bacterial endosymbiont genome that co-evolved with the nuclear genome — actively participates in regulating whole-organism aging, physical capacity, and metabolic homeostasis through peptide signals rather than merely through bioenergetic output. MOTS-c is the first identified mitochondrially encoded factor that actively regulates aging — a conceptual breakthrough as significant as its specific pharmacological profile.
MOTS-c is often described as an “exercise mimetic” — a molecule that recapitulates some of the metabolic benefits of physical exercise at the cellular and molecular level. This characterization is grounded in two complementary findings: exercise induces MOTS-c expression in skeletal muscle and plasma in humans, and exogenous MOTS-c administration mimics exercise-associated metabolic adaptations in animal models. The exercise mimetic label is scientifically meaningful but should be understood as partial — physical exercise produces a far broader range of adaptations than any single signaling peptide can replicate.
The Mitochondrial Retrograde Signaling Paradigm
Understanding MOTS-c requires understanding the concept of mitochondrial retrograde signaling — the bidirectional communication between mitochondria and the nucleus that is now recognized as a fundamental mechanism of cellular homeostasis.
The classical view of mitochondria was of passive metabolic organelles that received instructions from the nuclear genome through anterograde (nucleus-to-mitochondria) signaling while providing only energy (ATP) and metabolites in return. The discovery of mitochondrial retrograde signaling reversed this picture: mitochondria actively communicate their functional status to the nucleus through multiple signals — reactive oxygen species, metabolites, calcium, and, as MOTS-c revealed, peptides encoded within the mitochondrial genome itself.
MOTS-c occupies a remarkable position in this retrograde signaling paradigm. Under basal conditions, MOTS-c is found primarily in the cytoplasm and associated with mitochondria. Under metabolic stress conditions — including glucose restriction, serum deprivation, oxidative stress, exercise, and aging — MOTS-c translocates into the nucleus within 30 minutes of stress induction, where it directly regulates nuclear gene expression. This translocation is AMPK-dependent and ROS-modulated, creating a feedback loop between cellular energy status, AMPK activation, and MOTS-c nuclear regulatory activity.
Once in the nucleus, MOTS-c regulates genes containing antioxidant response elements (AREs) — gene regulatory sequences that coordinate the cellular response to oxidative and metabolic stress, driving expression of protective, anti-aging, and stress adaptation programs. Heat shock factor 1 (HSF1) has been identified as a key transcription factor mediating MOTS-c’s nuclear gene regulation — and siRNA knockdown of HSF1 reverses MOTS-c’s protective effects against metabolic stress, establishing HSF1 as a required downstream effector.
This nucleus-entering behavior is extraordinarily unusual for a small 16-amino acid peptide that originates in mitochondria and represents a form of bidirectional mitochondrial-nuclear communication not previously described for any mitochondrially encoded molecule.
Mechanism of Action
Primary mechanism — Folate cycle inhibition and AICAR-AMPK activation: MOTS-c’s primary biochemical mechanism involves inhibition of the folate cycle and its tethered de novo purine biosynthesis pathway. This inhibition causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — an endogenous nucleotide intermediate that is the most potent known endogenous activator of AMPK (AMP-activated protein kinase). The full mechanism is: MOTS-c inhibits methionine-folate cycle → de novo purine biosynthesis is suppressed → AICAR accumulates → AICAR phosphorylates and activates AMPK → AMPK drives downstream metabolic adaptations.
AMPK activation and downstream metabolic effects: AMPK is the master cellular energy sensor — often described as a “fuel gauge” — that is activated when cellular ATP falls relative to AMP/ADP. AMPK activation coordinately promotes catabolic energy-generating processes (glucose uptake, fatty acid oxidation, mitochondrial biogenesis) while suppressing anabolic energy-consuming processes (protein synthesis, lipogenesis, gluconeogenesis). MOTS-c activates AMPK through AICAR accumulation, thereby engaging the same metabolic adaptation program triggered by exercise and caloric restriction. AMPK activation in skeletal muscle specifically drives GLUT4 upregulation and glucose transporter translocation to the cell surface — the mechanism by which MOTS-c improves insulin sensitivity and glucose uptake.
Retrograde nuclear translocation and gene regulation: Under metabolic stress, exercise, or aging conditions, MOTS-c translocates to the nucleus in an AMPK-dependent manner and regulates expression of genes containing antioxidant response elements (AREs). Nuclear MOTS-c regulates gene programs related to metabolism, proteostasis (protein quality control), and longevity pathways. GSEA analysis from RNA-seq data in MOTS-c-treated skeletal muscle confirmed regulation of AMPK signaling, glycolysis, central carbon metabolism, and longevity pathway gene sets.
SIRT1 and PGC-1alpha activation: AMPK activated by MOTS-c’s AICAR-mediated mechanism drives SIRT1 (sirtuin 1) activation and PGC-1alpha induction — two master regulators of mitochondrial biogenesis, oxidative metabolism, and anti-aging gene programs. This establishes MOTS-c as an upstream activator of one of the most studied anti-aging molecular axes in biology.
Anti-inflammatory effects: MOTS-c reduces levels of pro-inflammatory cytokines and increases anti-inflammatory mediators through AMPK-dependent pathways, contributing to its effects on insulin sensitivity and metabolic disease. Chronic low-grade inflammation (inflammaging) is a central pathological mechanism of aging-related metabolic dysfunction, and MOTS-c’s anti-inflammatory activity through AMPK-SIRT1 represents a mechanistically relevant protective effect.
Skeletal muscle metabolism: MOTS-c’s primary target organ is skeletal muscle. In skeletal muscle, MOTS-c regulates glycolysis, amino acid metabolism, protein homeostasis, and myoblast adaptation to metabolic stress — a multi-pathway engagement that explains why MOTS-c exercise-induction in skeletal muscle drives systemic metabolic adaptation.
Published Research
Study 1 — Foundational Discovery: MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance
Authors: Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (University of Southern California, NIH) Year: 2015 Journal: Cell Metabolism PMID: 25738459 Full text: https://pubmed.ncbi.nlm.nih.gov/25738459/
This landmark Cell Metabolism paper — the discovery publication for MOTS-c — reported the identification of a 51-base pair short open reading frame within the mitochondrial 12S rRNA encoding a functional 16-amino acid peptide (MOTS-c), establishing for the first time that the mitochondrial genome harbors a peptide-coding sequence beyond its previously characterized inventory.
MOTS-c was identified by bioinformatic analysis of the mitochondrial genome for hidden sORFs, with expression verified using HeLa-rho0 cells (devoid of mitochondrial DNA), which showed complete absence of MOTS-c transcripts and peptide — confirming mitochondrial genome origin.
Phylogenetic analysis confirmed significant positive selection on the first 11 amino acid residues of MOTS-c across 14 mammalian species, indicating strong evolutionary conservation of a functionally important sequence within one of the most rapidly mutating genomes in biology.
The primary cellular mechanism was established: MOTS-c inhibits the methionine-folate cycle and de novo purine biosynthesis, leading to AICAR accumulation and AMPK activation — mechanistically connecting MOTS-c to the central cellular energy sensing pathway.
In high-fat diet-induced obese mice, MOTS-c treatment prevented diet-induced obesity and insulin resistance. In aged mice, MOTS-c treatment reversed age-dependent insulin resistance. These in vivo findings established MOTS-c as a systemically active peptide with anti-obesity and insulin-sensitizing properties relevant to both dietary and aging-associated metabolic dysfunction.
The authors concluded that these results suggest mitochondria may actively regulate metabolic homeostasis at the cellular and organismal level via peptides encoded within their genome — a conceptual conclusion as important as the specific findings.
Study 2 — Exercise Induction in Humans and Physical Performance Enhancement Across All Ages
Authors: Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C (USC, University of Auckland) Year: 2021 Journal: Nature Communications PMID: 33473109 Full text: https://www.nature.com/articles/s41467-020-20790-0
This Nature Communications study addressed two critical research questions simultaneously: whether MOTS-c is exercise-induced in humans, and whether exogenous MOTS-c can enhance physical performance across the entire aging spectrum in mice — establishing the “exercise mimetic” characterization and the aging biology relevance with rigorous evidence.
In sedentary healthy young male human volunteers who exercised on a stationary bicycle, MOTS-c levels in skeletal muscle increased approximately 11.9-fold after exercise (P equal to 0.0098) and returned partially to baseline after 4 hours of rest. Serum MOTS-c levels increased approximately 50% during and after exercise (P equal to 0.0011) and returned to baseline after rest — directly establishing MOTS-c as an exercise-induced peptide in humans, not only in animal models.
Systemic MOTS-c treatment in mice significantly enhanced treadmill performance in young (2 month), middle-aged (12 month), and old (22 month) mice — an approximately 2-fold improvement across all age groups. This age-independent enhancement demonstrated that MOTS-c’s physical performance benefits are not specific to any life stage.
MOTS-c regulated nuclear genes in skeletal muscle related to metabolism and proteostasis, glycolysis, amino acid metabolism, and longevity pathway gene sets as identified by Gene Set Enrichment Analysis on RNA-seq data from treated skeletal muscle.
HSF1 (heat shock factor 1) was identified as a putative transcription factor mediating MOTS-c’s nuclear gene regulation effects, with siRNA knockdown of HSF1 reversing MOTS-c-dependent stress resistance — establishing a required downstream effector.
Late-life initiated intermittent MOTS-c treatment (begun at 23.5 months of age, administered 3 times weekly) improved grip strength, gait (stride length), and physical performance in the oldest mice — animals that could no longer run. This late-life intervention showed a trend toward increased median lifespan (6.4%) and maximum lifespan (7.0%) and reduced hazard ratio (0.654), though the authors appropriately noted that larger cohorts will be needed to confirm lifespan effects.
Study 3 — Exercise Training Increases Skeletal Muscle MOTS-c Expression in Rodents; Acute Administration Improves Exercise Performance
Authors: Hyatt JP (East Carolina University) Year: 2022 Journal: Physiological Reports PMID: 35808870 Full text: https://pubmed.ncbi.nlm.nih.gov/35808870/
This study directly characterized the relationship between exercise training, MOTS-c accumulation in trained skeletal muscle, and the effect of acute MOTS-c supplementation on exercise performance — providing quantitative data on the exercise-MOTS-c interaction in rodents.
Four to eight weeks of voluntary running increased MOTS-c protein expression approximately 1.5 to 5-fold in trained rodent skeletal muscles (plantaris, medial gastrocnemius, tibialis anterior) compared to sedentary controls — confirming that MOTS-c accumulates within trained skeletal muscle in proportion to training volume.
This MOTS-c increase coincided with elevations in mitochondrial DNA (mtDNA), reflecting the mitochondrial genome expansion that accompanies aerobic training — consistent with more mitochondria producing more MOTS-c per cell.
The MOTS-c elevation from training was sustained for 4 to 6 weeks of detraining, indicating that MOTS-c persists in skeletal muscle well after cessation of training, possibly contributing to retention of some exercise adaptations during detraining periods.
A single dose of MOTS-c (15 mg/kg) administered to untrained mice improved total running time by 12% and total running distance by 15% during an acute exercise test — directly demonstrating that exogenous MOTS-c administration produces measurable acute exercise performance enhancement in previously untrained animals.
MOTS-c protein translocated from the cytoplasm into the nucleus in mouse soleus muscles 1 hour following a 90-minute downhill running challenge — confirming the retrograde nuclear translocation phenomenon in the context of exercise-induced metabolic stress.
Study 4 — Comprehensive Mechanistic Review: MOTS-c in Stress, Metabolism, and Aging
Authors: Liu Y et al. (multiple Chinese academic centers) Year: 2023 Journal: Journal of Translational Medicine (Springer) PMID: 36670507 Full text: https://link.springer.com/article/10.1186/s12967-023-03885-2
This comprehensive peer-reviewed review synthesized the mechanistic evidence for MOTS-c across stress biology, metabolism regulation, and aging-related pathologies — providing the most current mechanistic framework for MOTS-c research applications.
MOTS-c is primarily activated by stress and exercise, with expression decreasing with aging — establishing the age-related decline in endogenous MOTS-c as a potential contributor to the progressive loss of metabolic homeostasis characteristic of aging.
Under metabolic stress (glucose restriction, serum deprivation, oxidative stress), MOTS-c translocates to the nucleus within 30 minutes of stress induction through an AMPK-dependent mechanism — with pharmacological inhibition of AMPK preventing this nuclear translocation. Nuclear translocation forms a positive feedback loop: AMPK activates MOTS-c nuclear translocation, which in turn regulates ARE-containing genes, which further support AMPK-mediated stress adaptation.
The review characterized MOTS-c’s role in age-related pathologies including type 2 diabetes (through GLUT4 upregulation and insulin sensitivity restoration in skeletal muscle), cardiovascular diseases (through anti-inflammatory and cardioprotective mechanisms), osteoporosis (through bone metabolism regulation), and neurological conditions including Alzheimer’s disease research models.
The folate-AICAR-AMPK pathway was identified as the primary mechanistic axis — MOTS-c inhibits the methionine-folate cycle and de novo purine biosynthesis, accumulates AICAR, which activates AMPK, which activates SIRT1 and PGC-1alpha, driving the full metabolic adaptation program.
Study 5 — MOTS-c and Diabetes: Insulin Resistance, Type 1 DM, and Type 2 DM Mechanisms
Authors: Multiple groups (reviewed comprehensively in Diabetes and Metabolism Journal) Year: 2023 Journal: Diabetes and Metabolism Journal Full text: https://www.e-dmj.org/journal/view.php?doi=10.4093/dmj.2022.0333
This focused review synthesized the evidence specifically for MOTS-c’s role in diabetes — both type 1 and type 2 — characterizing the mechanistic connections between mitochondrial signaling and insulin action that make MOTS-c relevant to the most prevalent metabolic disease globally.
MOTS-c targets skeletal muscle as its primary organ for insulin sensitivity regulation, driving GLUT4 (glucose transporter type 4) upregulation through AMPK-dependent pathways — directly increasing the surface expression of the transporter responsible for insulin-stimulated glucose uptake in muscle and adipose tissue.
In type 2 diabetes models (high-fat diet-induced), MOTS-c treatment prevents obesity and hyperinsulinemia by regulating GLUT4 in an AMPK-dependent manner — addressing both the insulin resistance and the compensatory hyperinsulinemia that characterizes early type 2 diabetes.
In type 1 diabetes research models, MOTS-c has been investigated for its potential immunomodulatory effects on autoimmune beta-cell destruction — a mechanistically distinct application from its primary metabolic effects.
Systemic injection of MOTS-c can restore the level of MOTS-c in aged mice and successfully reverse age-related skeletal muscle insulin resistance — directly establishing that the age-related decline in endogenous MOTS-c is causally relevant to aging-associated insulin resistance, and that exogenous replacement can reverse this deficit.
Aging and the MOTS-c Decline
One of the most clinically significant findings in MOTS-c biology is the consistent observation that endogenous MOTS-c levels decline with aging. This decline correlates with the well-documented age-associated deterioration in metabolic efficiency, insulin sensitivity, physical capacity, and stress resilience. The convergence of multiple lines of evidence — MOTS-c levels decrease with age, endogenous MOTS-c is induced by exercise (which also decreases with aging), and exogenous MOTS-c administration reverses age-related metabolic and physical deficits — has generated a compelling hypothesis: the age-related decline in MOTS-c production contributes causally to metabolic aging, and MOTS-c restoration may represent a mitochondrial-genome-targeted approach to healthy aging.
This hypothesis is supported by the late-life intervention data from the Reynolds 2021 Nature Communications study, in which MOTS-c treatment begun at 23.5 months (approximately 70-75 human equivalent years) produced measurable improvements in physical capacity and a trend toward increased lifespan in mice — suggesting that even very late initiation of MOTS-c replacement may provide meaningful biological benefit.
The age-related MOTS-c decline also connects to a broader concept in aging biology: mitochondrial dysfunction is a hallmark of aging, characterized by reduced mitochondrial efficiency, increased reactive oxygen species production, and impaired mitochondrial quality control. MOTS-c represents a molecular readout of mitochondrial functional status — when mitochondria are healthy and stressed by exercise, MOTS-c is produced and exported. When mitochondria are aged and dysfunctional, MOTS-c production declines. This positions MOTS-c as both a biomarker of mitochondrial aging and a potential therapeutic to restore some of the signaling lost as mitochondria age.
MOTS-c in the Broader Mitochondria-Derived Peptide Family
MOTS-c is one of several mitochondria-derived peptides now identified, each with distinct properties and research profiles. Understanding MOTS-c’s relationship to other MDPs provides context for its specific research significance.
Humanin (encoded by 16S rRNA) was the first MDP identified and is known primarily for neuroprotective and cytoprotective effects, particularly against Alzheimer’s disease-related amyloid toxicity. Humanin levels also decline with aging and correlate with longevity.
SHLP1-6 (short humanin-like peptides, from 16S rRNA) share some structural features with humanin and have diverse biological activities across metabolism, aging, and apoptosis regulation.
MOTS-c is uniquely distinguished from all other MDPs by its 12S rRNA origin, its primary mechanism through folate cycle disruption and AMPK activation, its exercise-induced expression pattern, and — most unusually — its capacity for retrograde nuclear translocation and direct gene regulation. No other MDP has been demonstrated to enter the nucleus and regulate nuclear gene expression, making MOTS-c’s mechanism qualitatively distinct from the rest of the MDP family.
Research Limitations and Honest Assessment
MOTS-c research is scientifically rigorous and conceptually significant but remains predominantly preclinical. The primary evidence base is in rodent models, with human data currently limited to two key observations: exercise-induced MOTS-c expression in skeletal muscle and plasma in young healthy males (Reynolds 2021), and correlational studies between circulating MOTS-c levels and metabolic parameters in human populations.
No completed human clinical trials of exogenous MOTS-c administration for any therapeutic indication have been published, though CohBar, Inc. (a biotechnology company co-founded by MOTS-c co-discoverer Pinchas Cohen) has been developing MOTS-c analogs with improved pharmacokinetics for clinical investigation. Human pharmacokinetic and pharmacodynamic data for the native 16-amino acid MOTS-c peptide remain limited.
The human correlational data on circulating MOTS-c and metabolic parameters are mixed — associations with insulin sensitivity appear to depend on context (lean versus obese populations, age, exercise status) and do not map consistently across all populations studied, indicating that endogenous MOTS-c levels are not a simple readout of metabolic health in humans.
Current Research Status
MOTS-c is not FDA-approved for any therapeutic indication. It is classified as an experimental research compound. Research is active at multiple levels: basic mechanistic studies of MOTS-c retrograde signaling and nuclear gene regulation, in vivo animal studies of MOTS-c in aging, diabetes, cardiovascular disease, obesity, and physical performance, human biomarker studies correlating circulating MOTS-c with disease risk and aging parameters, and pharmaceutical development of MOTS-c analogs with improved pharmacokinetic profiles. The broader mitochondria-derived peptide field is one of the most rapidly developing areas in translational aging biology.
Reconstitution Note
MOTS-c is a synthetic 16-amino acid peptide. Bacteriostatic water is the standard reconstitution solvent. MOTS-c dissolves readily in aqueous solution. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the MOTS-c product page: https://roguecompounds.com/product/mots-c/